Threshold Pharma begins dosing of cancer drugs evofosfamide and ipilimumab in Phase I trial

US-based biopharmaceutical firm Threshold Pharmaceuticals has begun dosing patients in a Phase I clinical trial of evofosfamide in combination with ipilimumab to treat various cancers.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news